TCIM
ALDX icon

TIAA CREF Investment Management’s Aldeyra Therapeutics ALDX Stock Holding History

TIAA CREF Investment Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$278K Buy
30,792
+8,363
+37% +$71.1K ﹤0.01% 2799
2018
Q4 		$186K Sell
22,429
-617
-3% -$6.32K ﹤0.01% 2889
2018
Q3 		$318K Sell
23,046
-1,376
-6% -$11.2K ﹤0.01% 2872
2018
Q2 		$194K Buy
+24,422
New +$195K ﹤0.01% 3039

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TIAA CREF Investment Management's ALDX Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Aldeyra Therapeutics (ALDX) stake by 37% in Q1 2019, buying an estimated $71.1K and bringing the position to 30,792 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #2799.

TIAA CREF Investment Management first reported a position in ALDX in Q2 2018 and has held it in 4 quarters since. The position peaked at $318K in Q3 2018. 79 funds tracked by Wall St. Rank hold ALDX as of Q1 2019.

  • TIAA CREF Investment Management held 30,792 shares of Aldeyra Therapeutics worth $278K as of Q1 2019.
  • TIAA CREF Investment Management bought 8,363 Aldeyra Therapeutics shares in Q1 2019, an estimated $71.1K.
  • Aldeyra Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2799 holding.
  • TIAA CREF Investment Management first reported a position in Aldeyra Therapeutics in Q2 2018 and has held it in 4 quarters since.
  • TIAA CREF Investment Management's Aldeyra Therapeutics position peaked at $318K in Q3 2018.
  • 79 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.